Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Novavax Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.84 (market cap $6.04B), while Novavax Inc trades at $12.7 (market cap $1.82B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 3.3× Novavax Inc's market cap, and Iovance Biotherapeutics Inc. Common Stock is more actively traded (14,805,993 versus 6,198,505). Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Novavax Inc for 59 Days on average.
| IOVA | NVAX | |
|---|---|---|
Market Cap | $6.04B | $1.82B |
Volume | 14,805,993 | 6,198,505 |
Sector | Health | Health |
52-Week High | $14.82 | $12.56 |
52-Week Low | $1.81 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $5.97B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
